TC
ALNY icon

Truvestments Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Truvestments Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Hold
60
– – ﹤0.01% 701
2026
Q1 		$19.9K Hold
60
– – ﹤0.01% 642
2025
Q4 		$23.9K Buy
60
+3
+5% +$1.33K ﹤0.01% 559
2025
Q3 		$26.1K Hold
57
– – ﹤0.01% 545
2025
Q2 		$18.7K Hold
57
– – ﹤0.01% 546
2025
Q1 		$15.4K Hold
57
– – ﹤0.01% 592
2024
Q4 		$13.4K Hold
57
– – ﹤0.01% 556
2024
Q3 		$15.7K Buy
+57
New +$14.8K ﹤0.01% 524

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truvestments Capital's ALNY Position: Q2 2026 in Review

Truvestments Capital held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 60 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Truvestments Capital first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $26.1K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Truvestments Capital held 60 shares of Alnylam Pharmaceuticals worth $18.1K as of Q2 2026.
  • Truvestments Capital left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #701 holding.
  • Truvestments Capital first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Truvestments Capital's Alnylam Pharmaceuticals position peaked at $26.1K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.